Search

Nutri-T offers exceptional performance with cells starting at low initial seeding concentrations.

The FDA approval of Kymriah marks the first CAR-T cell-based gene therapy available in the US

The question that’s on everyone’s lips: how can developers tackle solid tumors and bring cell therapy to millions?

From Carl June to Peter Marks to Kiran Mazumdar-Shaw; check out our thought provoking interviews with some of the biggest names in the pharma field.

Our latest eBook gives a snapshot of innovation in cell and gene therapies

A whistle-stop tour of the mechanisms, benefits, manufacturing challenges, and clinical potential of CAR T cells, TCR T cells, TILs, and NK cells.

Lore Gruenbaum discusses The Leukemia & Lymphoma Society, advances in blood cancers, and the role of nonprofits.

Looking back on 12 months of cell and gene therapy research.

What is the single greatest challenge facing the cell and gene therapy industry in 2021?

Miguel Forte argues it’s time to fine tune the way we target solid tumors...